FDA says opioid labels must include information about naloxone

first_img WASHINGTON — The Food and Drug Administration announced Thursday that it would require drug manufacturers to include information about naloxone, the overdose-reversal medication, on the labels of opioid painkillers.The move comes just weeks after the federal government released new data showing that U.S. drug overdose deaths reached an all-time high in 2019, surpassing the previous peak recorded two years earlier. More recently, the Covid-19 pandemic has led to another increase in overdose deaths as the unemployment rate has skyrocketed and Americans have lost access to health insurance and to many in-person health services like addiction clinics or syringe exchanges.Naloxone, often referred to by the brand name Narcan, has been used in the U.S. to reverse opioid overdoses since 1971. While it’s often prescribed in an injectable form, it’s also commonly sold as a nasal spray or a mechanized auto-injector, which make the medication easier for people without medical training to deliver.advertisement Scott Olson/Getty Images Tags opioidspharmaceuticals Newsletters Sign up for Morning Rounds Your daily dose of news in health and medicine. HealthFDA says opioid labels must include information about naloxone Leave this field empty if you’re human: The FDA’s announcement is the latest step in a nationwide effort to distribute naloxone more widely, both to people who use drugs and people likely to witness opioid overdoses.advertisement Please enter a valid email address. Privacy Policy Opioid overdoses have skyrocketed amid the coronavirus, but states are nevertheless slashing addiction treatment program budgets  The Department of Health and Human Services recommended in 2018 that physicians prescribe naloxone alongside opioids to patients at high risk for overdose, like those on high opioid doses or those who take the pain drugs alongside benzodiazepines, a class of medications used to treat anxiety and other health conditions.In recent years commercial health insurers and local governments have also moved to make naloxone more widely available, including covering the medication at no cost and issuing “standing orders” so that any individual can purchase naloxone at a pharmacy, even without a prescription. @levfacher Related: The FDA also said it would require similar labels for the three approved drugs used to treat opioid addiction: methadone, buprenorphine, and naltrexone.While the move is likely to result in increased awareness and use of naloxone among patients who use prescription opioids for pain, it’s unclear whether it will help reduce overdose deaths for people who use illicit opioids like heroin.Fentanyl, the ultra-powerful synthetic opioid that illicit drug manufacturers often include in illegally manufactured pills or in heroin itself, is also a major driver of drug overdose deaths. About the Author Reprints “Today’s action can help further raise awareness about this potentially life-saving treatment for individuals that may be at greater risk of an overdose and those in the community most likely to observe an overdose,” Stephen Hahn, the FDA commissioner, said in a statement. [email protected] Washington Correspondent Lev Facher covers the politics of health and life sciences. Lev Facher By Lev Facher July 23, 2020 Reprintslast_img read more

Details